Breaking News, Collaborations & Alliances

Regeneron, Intellia Expand CRISPR-Based Therapies Research Pact

Combines Intellia’s genome editing platform with Regeneron’s antibody-targeted viral vector delivery technologies for neurological and muscular diseases.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Regeneron Pharmaceuticals, Inc. and Intellia Therapeutics, Inc. expanded their research collaboration to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases. This builds on the success of the companies’ existing collaboration and combines both companies’ biology and technology expertise. The collaboration will leverage Regeneron’s antibody-targeted adeno-associated virus (AAV) vectors and delivery systems and Intellia’s Nme2 CRISPR/Cas9 (N...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters